Alethio Therapeutics
Alethio Therapeutics is a University of Oxford spin-out founded in 2021 (formerly Alethiomics) and based in Abingdon, UK.
Position in SVTRnew
Snapshot 2026-11-06- Startup SignalsRankedof 2,346
- Life SciencesRankedof 250
- AI for ScienceRankedof 116
- Drug DiscoveryRankedof 72
About
Alethio Therapeutics is a University of Oxford spin-out founded in 2021 (formerly Alethiomics) and based in Abingdon, UK. Using its ARTEMIS target-discovery engine, which includes a machine-learning target-prioritisation pipeline, and a large repository of myeloproliferative neoplasm (MPN) patient cells, it develops mutation-agnostic antibody therapies; lead candidate ATX-011 targets essential thrombocythemia.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 11
Investor· 5
Founders / team· 3
Funding history
- 2026-11-05Series A$90M
Investors · Sofinnova Partners, RA Capital, Oxford Science Enterprises, Cancer Research Horizons, University of OxfordSource · alethiotherapeutics.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Alethio Therapeutics
Alethio Therapeutics is a University of Oxford spin-out founded in 2021 (formerly Alethiomics) and based in Abingdon, UK.
Series A · 2026-11
—
United States
BusinessLatest roundTotal raisedDate- Electra Therapeutics
Develops antibody drugs targeting SIRP.
IPO · $302M · 2026-09
$302M - insitro
ML-driven drug discovery modeling high-throughput cellular data and human clinical/genomic data, with in-house pipeline and pharma partnerships
$400M
$400M - Odyssey Therapeutics
Small-molecule and protein therapeutics developed with AI and machine learning
Series C · $101M · 2023-12
$101M
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders…
Series B · 2026-09
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - HuidaGene Therapeutics
Gene therapies for genetic diseases built on CRISPR/Cas gene editing and a proprietary AAV delivery platform; lead programs include HG004 for RPE65-re…
—
Europe
BusinessLatest roundTotal raisedDate- Relation Therapeutics
Multi-omics plus active graph machine learning to discover and validate novel drug targets, partnered with GSK (fibrosis and osteoarthritis)
Undisclosed · $61M · 2025-12
$61M - Alchemab Therapeutics
AI-based discovery and development of therapeutic antibodies from "naturally resistant" populations
Series A · $32M · 2025-09
$32M - Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M
Other / unspecified
BusinessLatest roundTotal raisedDate- Astellas Pharma
Research, manufacturing and sale of prescription drugs in oncology, ophthalmology, urology, immunology and women's health.
— - Elixion Biotech
Cancer drug target discovery platform driven by quantum physics, causal biology, multi-omics and AI
— - Altis Labs
AI imaging biomarker platform across solid tumor types and therapeutic areas
Series A · $31M · 2026-09
$31M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
39 Life Sciences deals in the last 24 months · 34 at a nearby stage · 1 in United Kingdom
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 3 in United Kingdom
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 10 at a nearby stage · 1 in United Kingdom
Request intro →Accel
12 Life Sciences deals in the last 24 months · 9 at a nearby stage · 2 in United Kingdom
Request intro →GV
12 Life Sciences deals in the last 24 months · 6 at a nearby stage · 3 in United Kingdom
Request intro →Catalio Capital Management
9 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in United Kingdom
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.